Memantina Qualigen (Memantine Hydrochloride)

Memantine blocks the NMDA‑type glutamate receptor in a non‑competitive manner, reducing excessive calcium entry into neurons. This limits glutamate‑mediated excitotoxicity, which is thought to contribute to neuronal loss and cognitive decline in Alzheimer’s disease.

The dose of Memantina Qualigen is individualized by the prescribing clinician. Treatment typically starts at a low dose that is gradually increased to the target maintenance dose, based on the patient’s response and tolerability.

The pregnancy safety category for memantine is unknown. Because potential risks cannot be ruled out, the product should be avoided during pregnancy and lactation unless the expected benefit justifies the potential hazard to the fetus or infant.

To request Memantina Qualigen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

The primary alternative class for Alzheimer’s disease is acetylcholinesterase inhibitors such as donepezil. While those agents increase acetylcholine levels, memantine modulates glutamatergic activity. Clinically, memantine is often added to or used when patients no longer respond adequately to acetylcholinesterase inhibitors, offering a different mechanism of action.

Store Memantina Qualigen at temperatures below 25 °C in its original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Memantina Qualigen is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious adverse events include seizures, severe skin reactions such as Stevens‑Johnson syndrome, hepatic dysfunction, and emergent psychiatric symptoms like suicidal thoughts or psychosis. Patients should seek immediate medical attention if any of these occur.

Memantina Qualigen is contraindicated in patients with known hypersensitivity to memantine or any excipients in the tablet. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA antagonists.